Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk.
The proto-oncogene MDM2 inhibits p53 and plays a key role in cell growth control and apoptosis. Identification of two antagonizing MDM2 polymorphisms, SNP285 and SNP309, affecting cancer risk through modulation of Sp1 transcription factor binding, shed new light on the biological activity and phylogeny of this gene.
Section of Oncology, Institute of Medicine, University of Bergen; Bergen, Norway. stian.knappskog@med.uib.no
Stian
S
Knappskog
Per E
PE
Lønning
D006801:Humans; D009369:Neoplasms / Q000209:etiology / Q000235:genetics / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D011485:Protein Binding / Q000235:genetics; D000090063:Proto-Oncogene Mas; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics* / Q000378:metabolism; D012307:Risk Factors; D016329:Sp1 Transcription Factor / Q000235:genetics* / Q000378:metabolism; D014158:Transcription, Genetic; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D016329:Sp1 Transcription Factor; D016159:Tumor Suppressor Protein p53; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2